About
VESSL Therapeutics develops cell-based therapies for patients who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities. Its core technology is based on an integrative approach for the treatment of cardiovascular disease. VESSLs two leading products, MultiGeneAngio and MultiGeneGraft, have been approved by the FDA for clinical studies, and two phase 1/2 clinical trials with MultiGeneAngio have been completed. MultiGeneAngio is a combination of two cell types and two genes, and MultiGeneGraft is the combination of cells, genes, and a synthetic graft. These two technologies are used in therapies for patients with peripheral artery disease and coronary artery disease, and for patients with renal disease requiring hemodialysis. The companys products are based on the patients own cells, isolated from a short vein segment taken from the patients arm under local anesthesia. The isolated cells are activated by the insertion of specific genes and then reintroduced to the patient. The FDA has granted an Investigational New Drug (IND) authorization for MultiGeneGraft.
Funding history · 2 rounds · $30.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is VESSL Therapeutics' primary focus?
- VESSL Therapeutics develops cell-based therapies for patients with cardiovascular and other vascular-related conditions.
- What are VESSL Therapeutics' two leading products?
- VESSL Therapeutics' two leading products are MultiGeneAngio and MultiGeneGraft.
- Have VESSL Therapeutics' products received FDA approval for clinical studies?
- Yes, MultiGeneAngio and MultiGeneGraft have been approved by the FDA for clinical studies. The FDA has also granted an Investigational New Drug (IND) authorization for MultiGeneGraft.
- What is the clinical trial status of MultiGeneAngio?
- Two phase 1/2 clinical trials with MultiGeneAngio have been completed.
- What conditions are VESSL Therapeutics' technologies used to treat?
- VESSL Therapeutics' technologies are used in therapies for patients with peripheral artery disease, coronary artery disease, and renal disease requiring hemodialysis.
- How does VESSL Therapeutics' cell-based therapy work?
- VESSL Therapeutics' products are based on the patient's own cells, isolated from a short vein segment, activated by the insertion of specific genes, and then reintroduced to the patient.
- What was VESSL Therapeutics' total funding raised?
- VESSL Therapeutics has raised a total of $30,000,000. For full financing history, please refer to startupim.
- When did VESSL Therapeutics complete its most recent funding round and who was the lead investor?
- In April 2021, VESSL Therapeutics completed an undisclosed funding round of $16,000,000, with RunYoung Technology Transfer Center as the lead investor.
- When was VESSL Therapeutics founded?
- VESSL Therapeutics was founded in October 2000.